1700 Owens Street
About Nurix Inc.
Nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. Nurix is a leader in discovering a new class of drugs that work by modulating E3 ligases within the ubiquitin proteasome system (UPS), a regulatory network that controls protein levels within the cell.
Nurix’s scientific team has established an innovative drug discovery platform that can either increase the levels of specific proteins through direct inhibition of ligase function, or eliminate disease proteins by harnessing ligases to ubiquitinate and redirect them to the proteasome for degradation. A key distinction of degrader technology over classical small molecule inhibition is that it has the potential to target proteins previously considered ‘undruggable’. Nurix was founded by internationally recognized experts in the UPS field and received its initial funding from leading life science investors, Third Rock Ventures and The Column Group.
In 2019, Nurix entered into a multi-year strategic collaboration with Gilead to discover targeted protein degraders in multiple therapeutic areas. Nurix is based in San Francisco’s biotechnology hub, Mission Bay – where academia and industry come together for cutting-edge life-saving research.
12 articles with Nurix Inc.
10/11/2019Companies strengthen their leadership teams and boards of directors with these appointments.
Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases
Collaboration will Leverage Nurix’s Proprietary Drug Discovery Platform to Identify Novel Agents that Induce Degradation of Specified Drug Targets
The focus will be on discovering drugs that use the body’s natural protein control processes.
Nurix Launches Collaboration With Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute To Expand Its Drug Discovery Program
Two San Francisco Startups, Element Science And Nurix, Reap Cash From Third Rock Ventures' Rich Funding Round